This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ahmed, N. Articles by Gottschalk, S. Search for Related Content PubMed PubMed Citation Articles by Ahmed, N. Articles by Gottschalk, S.

Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells

¹ Center for Cell and Gene Therapy, ² Texas Children's Cancer Center, ³ The Breast Center, Departments of ⁴ Pediatrics, ⁵ Medicine, ⁶ Pathology, ⁷ Immunology, ⁸ Neurosurgey, ⁹ Neuroscience, ¹⁰ Molecular and Cellular Biology, and ¹¹ Molecular Virology and Microbiology, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital, Houston, Texas; ¹² Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt am Main, Germany; and ¹³ St. Jude Children's Research Hospital, Memphis, Tennessee

Requests for reprints: Stephen Gottschalk, Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3-3320, Houston, TX 77030. Phone: 832-824-4179; Fax: 832-825-4732; E-mail: smg{at}bcm.edu.

Medulloblastoma is a common malignant brain tumor of childhood. Human epidermal growth factor receptor 2 (HER2) is expressed by 40% of medulloblastomas and is a risk factor for poor outcome with current aggressive multimodal therapy. In contrast to breast cancer, HER2 is expressed only at low levels in medulloblastomas, rendering monoclonal antibodies ineffective. We determined if T cells grafted with a HER2-specific chimeric antigen receptor (CAR; HER2-specific T cells) recognized and killed HER2-positive medulloblastomas. Ex vivo, stimulation of HER2-specific T cells with HER2-positive medulloblastomas resulted in T-cell proliferation and secretion of IFN- and interleukin 2 (IL-2) in a HER2-dependent manner. HER2-specific T cells killed autologous HER2-positive primary medulloblastoma cells and medulloblastoma cell lines in cytotoxicity assays, whereas HER2-negative tumor cells were not killed. No functional difference was observed between HER2-specific T cells generated from medulloblastoma patients and healthy donors. In vivo, the adoptive transfer of HER2-specific T cells resulted in sustained regression of established medulloblastomas in an orthotopic, xenogenic severe combined immunodeficiency model. In contrast, delivery of nontransduced T cells did not change the tumor growth pattern. Adoptive transfer of HER2-specific T cells may represent a promising immunotherapeutic approach for medulloblastoma. [Cancer Res 2007;67(12):5957–64]